secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001193125-24-272860
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam reports BEAM-101 Phase 1/2 data: all 7 patients achieved >60% HbF, resolved anemia; ESCAPE proof-of-concept in NHPs
--------------------------------------------------------------------------------

- Seven patients dosed with BEAM-101 achieved HbF >60%, HbS <40%, and resolution of anemia; no VOCs post-engraftment.
- Mean neutrophil engraftment 17.1 days, platelet 19.1 days; one death from busulfan-related respiratory failure deemed unrelated.
- ESCAPE antibody conditioning in NHPs enabled long-term engraftment of base-edited HSCs with >80% HbF-containing cells.
- BEAM-103 mAb dosing was well tolerated without transfusions or supportive care; minor declines in neutrophils/platelets.
- BEAM-302 initial clinical data from multiple cohorts now expected in first half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312524272860/0001193125-24-272860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312524272860/d903914d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-272860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer